SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors anticipate a major catalyst from the final survival event in the Phase 3 REGAL trial, with the stock seeing intense volatility driven by a massive short squeeze. Community members are actively debating the timing of a potential buyout and the drug's long-term curative potential, while the tightening liquidity and extreme borrow costs continue to trap short sellers in a high-pressure environment.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. The company operates through the OSS and OSS Europe segments. One Stop Systems was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is seeing significant attention from the investment community due to its strategic positioning in ruggedized edge computing, which is essential for the expanding physical AI, robotics, and defense infrastructure sectors. Discussions are heavily focused on the company's strong contract pipeline, recent earnings performance, and positive momentum from upcoming index inclusion, with many participants viewing it as an under-the-radar player poised to capitalize on the shift of AI workloads beyond traditional data centers.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is currently trending as investors rotate capital from high-beta AI and semiconductor trades into defensive, cash-flow-generative healthcare stocks. Community discussion is heavily focused on this defensive rotation, with traders noting the stock's steady performance and institutional interest as a reliable hedge against broader market volatility.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is trending due to significant sector rotation as investors shift capital from overextended large-cap tech into the biotech space. The community is actively discussing bullish price structures, potential M&A activity, and biotech's role as a defensive rotation as broad markets search for direction.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as a top healthcare leader due to groundbreaking Phase 3 clinical data for its obesity and diabetes pipeline, which has ignited investor excitement regarding its long-term growth prospects. The community is actively discussing this news, alongside broader market rotation into defensive, high-quality pharmaceutical names as participants look to balance their portfolios.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is currently a major focus of community debate, with polarized discussions centering on the long-term potential of the network's shift toward a capped supply and upgraded architecture versus intense criticism regarding its significant price decline from previous highs. While some investors highlight the project's ongoing technical development and staking yields as an accumulation opportunity, others are aggressively shorting the asset, citing persistent lack of retail adoption and perceived stagnant growth.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund

The Healthcare sector is experiencing a significant defensive rotation as capital shifts from high-volatility technology stocks into established compounders like $XLV. Investors are closely monitoring key technical support levels and structural strength across pharmaceutical and biotech names, viewing the sector as a stable haven amidst rising market uncertainty and year-end portfolio positioning.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgent Power Solutions Inc. is trending as investors rotate capital into the energy infrastructure and data center buildout theme, fueled by a record-breaking backlog and strong guidance regarding AI load growth. The community is actively discussing its role as a critical bottleneck provider in the electrical distribution sector, with many viewing recent price volatility as institutional accumulation rather than distribution.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is currently experiencing high volatility as investors weigh its role as a critical supplier of indium phosphide substrates for AI data center infrastructure against concerns regarding lofty valuations and significant insider selling. The community remains sharply divided, with some highlighting the company's massive year-to-date gains and foundational position in the optical networking supercycle, while others warn of potential downside risks following share dilution and aggressive insider distribution.

ClearPoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

ClearPoint Neuro Inc

ClearPoint Neuro is trending as investors react to a significant robotic neuro-navigation system development and continued positive momentum from its gene therapy delivery platform. The community is actively debating the company's valuation versus its potential as a 'picks and shovels' play in the neuro-tech sector, with many focused on how the stock will perform given its high short interest and speculative growth profile.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million.
Mobile-health Network (NASDAQ:MNDR)read more...

Quoin Pharmaceuticals Garners Buzz After FDA’s Comments On Netherton Syndrome Lead Drug

Equity

The U.S. Food and Drug Administration indicated that a single Phase 3 trial of QRX003 could be enough to support approval in the U.S.

Quoin Pharmaceuticals Gains FDA Alignment, Eyes Streamlined Path to First Netherton Syndrome Treatment

Quoin Pharmaceuticals (NASDAQ:QNRX) reported a key regulatory milestone following a constructive Type C meeting with the U.S. Food and Drug Administration (FDA), potentially accelerating the development path for its lead candidate, QRX003, in the treatment of Netherton Syndrome, a rare and underserved genetic skin disorder.

QNRX Stock Soared A Whopping 39% Today: What’s Driving The Relentless Rally? 

A rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company said.

QNRX Stock Soars 300% After $104.5M Financing Through Private Placement

Quoin said that the purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.

Retail Buzz Intensifies Around Quoin Pharma Stock After Positive Pediatric Skin Study Data

The stock closed up 20% on Wednesday, driven by promising patient outcomes and no reported adverse events for its Pediatric Peeling Skin Syndrome (PSS) drug, with further treatment and evaluations planned.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Quoin Pharmaceuticals Ltd - ADR

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.45
Prev Close	$4.20
Open	$4.10
Dividend Yield	0.00%
50-Day Moving Average	$5.30
Beta	0.61
Avg. Volume	26,386.14
PE Ratio	-0.02

52-Week High	$41.80
52-Week Low	$3.25
Market Capitalization	$8.24M
EPS (Annual)	-$10.63
Price to Book	0.94
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

QNRXQuoin Pharmaceuticals Ltd - ADR

Latest QNRX News